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Bone turnover markersDenosumab has been shown to reduce newvertebral, nonvertebral, and hip fractures in postmenopausalwomen
with osteoporosis. In subjects who were treatment-naïve or previously treated with alendronate, denosumab
was associated with greater gains in bone mineral density (BMD) and decreases in bone turnover markers
when compared with alendronate-treated subjects. This trial was designed to compare the efﬁcacy and safety
of denosumab with risedronate over 12 months in postmenopausal women who transitioned from daily or
weekly alendronate treatment and were considered to be suboptimally adherent to therapy.
In this randomized, open-label study, postmenopausal women aged ≥55 years received denosumab 60 mg
subcutaneously every 6 months or risedronate 150 mg orally every month for 12 months. Endpoints included
percentage change from baseline in total hip BMD (primary endpoint), femoral neck, and lumbar spine BMD at
month 12, and percentage change from baseline in sCTX-1 at months 1 and 6. Safety was also assessed.
A total of 870 subjects were randomized (435, risedronate; 435, denosumab) who had a mean (SD) age of 67.7
(6.9) years, mean (SD) BMD T-scores of−1.6 (0.9),−1.9 (0.7), and−2.2 (1.2) at the total hip, femoral neck, and
lumbar spine, respectively, and median sCTX-1 of 0.3 ng/mL at baseline. At month 12, denosumab signiﬁcantly
increased BMD compared with risedronate at the total hip (2.0% vs 0.5%), femoral neck (1.4% vs 0%), and lumbar
spine (3.4% vs 1.1%; pb 0.0001 at all sites). Denosumab signiﬁcantly decreased sCTX-1 compared with risedronate
at month 1 (median change from baseline of −78% vs −17%; p b 0.0001) and month 6 (−61% vs −23%;
p b 0.0001). Overall and serious adverse events were similar between groups.
In postmenopausal women who were suboptimally adherent to alendronate therapy, transitioning to denosumab
was well tolerated and more effective than risedronate in increasing BMD and reducing bone turnover.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.ochin Hospital, AP-HP, Paris, France.
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Osteoporosis is deﬁned as a systemic skeletal disorder characterized
by compromised bone strength predisposing to an increased risk of
fracture [1–3]. Sustained beneﬁt of a therapeutic agent for a chronic
condition such as osteoporosis generally requires continued treatment.
While bisphosphonates are the most commonly used treatment for
postmenopausal osteoporosis, difﬁcult dosing regimens and multiple
side effects may limit drug adherence [4]. This poor adherence to
bisphosphonate therapy in osteoporosis is both common and associated
with unfavorable outcomes and increased treatment costs [5,6]. In
addition, if a patient sustains a low-trauma fracture or continues to have
low bone mineral density (BMD) while on treatment, some clinicians
may consider that a patient has failed therapy and may recommend
transition to another medication. For subjects who are suboptimally
treated with bisphosphonates under these circumstances, it is important
to understand whether they are appropriate for, and would receive
beneﬁt from, transitioning to a new therapy, such as one with a different
mechanism of action than bisphosphonates.
Denosumab has been approved in many countries for the treatment
of postmenopausal women with osteoporosis at increased or high risk
for fracture. Denosumab is a fully human monoclonal antibody against
RANKL, a cytokine that is an essential mediator for osteoclast formation,
function, and survival [7]. In postmenopausalwomenwith osteoporosis,
denosumab 60 mg administered subcutaneously every 6 months
signiﬁcantly reduced bone turnover markers, increased BMD, and
reduced new vertebral, hip, and nonvertebral fractures compared
with placebo in the pivotal 36-month fracture trial [8].
It has been shown that in subjects who were treatment-naïve or
previously treated with alendronate, transitioning to denosumab
treatment was associated with greater gains in BMD and decreases
in bone turnover markers when compared with subjects continuing on
alendronate treatment [9,10]. It is not known whether this observation
would be similar with other bisphosphonates, which is an important
consideration for women or their physicians who are considering a
change in therapy due to unsatisfactory treatment effect.
The purpose of this randomized, open-label trial was to compare the
safety and efﬁcacy of transitioning to denosumabor the bisphosphonate
risedronate for 12 months, in postmenopausal women who were
previously treatedwith daily orweekly alendronate andwere considered
to be suboptimally adherent to their current therapy.
Methods
Study design
This 12-month, multicenter, international (82 centers in Europe,
Australia, and Canada), randomized, open-label, parallel-group study
was conducted in postmenopausal women who had previously been
prescribed alendronate therapy, but had either stopped taking
alendronate or were currently taking alendronate, but demonstrated
suboptimal adherence to treatment.
Treatment
Subjects were randomized 1:1 to receive either denosumab 60mg
subcutaneously (SC) every 6months (Q6M) or risedronate orally (PO)
150mg once monthly (QM, one 75mg tablet on each of 2 consecutive
days) for 12 months. The protocol speciﬁed that all subjects were
required to take daily supplements of ≥1000 mg elemental calcium
and ≥800 IU vitamin D during the study.
Participants
Ambulatory, postmenopausal women aged ≥55years were eligible
if they had been previously prescribed alendronate therapy, with theﬁrst daily or weekly alendronate prescription ≥1 month prior to
screening, without limitation of alendronate treatment duration.
All subjects provided signed informed consent prior to initiation of
any study procedure.
With a 1:1 randomization ratio, a sample size of 362 evaluable
subjects in each treatment group would give N90% power to detect
a difference N1% at the total hip BMD at 12months using a two-sided
t-test at the 5% signiﬁcance level, assuming a common standard
deviation (SD) of 2.65%. Assuming a dropout rate of 10% in 12months,
the planned enrollment was 400 subjects in each treatment group,
with a total sample size for the study of approximately 800 subjects.
To be eligible to participate in this study, the subject must have
either stopped oral alendronate therapy before the screening visit, or
was still taking oral alendronate therapy (no washout period) with
low adherence, whichwas assessed by a score of b6 on theOsteoporosis
Speciﬁc Morisky Medication Adherence Scale (OS-MMAS). The OS-
MMAS is an osteoporosis-speciﬁc version of the MMAS, an 8-item
questionnaire that has been evaluated for reliability and validity [11].
Each of the 8 items captures a speciﬁc medication-taking behavior.
Scores from the OS-MMAS can range from 0 to 8 and have been
categorized into 3 levels of adherence: high (score = 8), medium
(6 ≤ score b 8), and low (score b 6). There was no inclusion criterion
based on BMD.
Key exclusion criteria included any prior or current treatment with
osteoporosis medication other than daily or weekly oral alendronate
therapy, hormone replacement therapy, and calcium and vitamin
D (use of raloxifene or calcitonin prior to initiation of alendronate
therapy was allowed); use of the following medications within
3 months of screening: tibolone, anabolic steroids or testosterone,
and glucocorticosteroids (≥5 mg prednisone equivalent per day
for N10 days or a total cumulative dose of ≥50 mg); contraindicated
or poorly tolerant of alendronate; signiﬁcantly impaired renal function;
previous participation in clinical trials with denosumab within the
preceding 12 months regardless of treatment; reported malignancy
within the last 5 years, except cervical carcinoma in situ or basal cell
carcinoma; and any metabolic bone disease that had the potential to
interfere with the interpretation of the ﬁndings. Vitamin D deﬁciency,
deﬁned as serum 25 (OH) vitamin D levels b20ng/mL,was an exclusion
criterion: repletion as conﬁrmed by a serum vitamin D level≥20ng/mL
was allowed and subjects were able to be re-screened only once.
The study was conducted in accordance with the Declaration of
Helsinki and the International Conference on Harmonization Good
Clinical Practice Guidelines, and the study protocol was approved
by an institutional review board for each study site.
Assessments
Bone mineral density
Dual-energy X-ray absorptiometry (DXA) scans were performed at
the proximal femur and lumbar spine (L1 to L4) at baseline and month
12 or end-of-study visit using GE Lunar or Hologic series scanners. The
same DXA machine was used for all study procedures for a particular
subject. The left side was used for all study procedures of the proximal
femur, unless prohibited (e.g., hip implant). If the right side was used at
screening, then the same side was used consistently throughout the
study. DXA scans were performed in duplicate, i.e., an initial scan and
a repeat scan (after repositioning the patient on the table between
measurements) at each visit, and analyzed by a central imaging vendor
(Synarc, Portland, OR, USA).
Biochemical markers
Measurement of the biochemical marker of bone turnover, serum C-
telopeptide of type I collagen (sCTX-1), was performed by Covance
Laboratory (Indianapolis, IN, USA). sCTX-1 measurements were taken
after an overnight fast and prior to the dose of investigational product
in a subset of subjects who agreed to participate in the bone marker
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risedronate; 84 denosumab). All samples were shipped to the central
laboratory for analysis and measured in multiple assays. Evaluation of
anti-denosumab antibodies in a subset of subjects receiving denosumab
was performed at day 1 and month 12 or at the end-of-study visit
with a screening immunoassay; any binding antibodieswere conﬁrmed
with a cell-based anti-denosumab binding antibody immunoassay for
neutralizing antibodies (PPD, Richmond, VA, USA).Statistical analysis
The primary endpoint was the mean percentage change from
baseline in total hip BMD at month 12. The secondary endpoints were
the mean percentage change in femoral neck and lumbar spine BMD
at month 12 and the median percentage change from baseline in
sCTX-1 at month 1. An exploratory endpoint was the median
percentage change from baseline in sCTX-1 at month 6. Safety was
assessed over the 12-month study through incidence of adverse events
(AEs) and serious adverse events (SAEs) thatwere collected throughout
the study.
The full analysis set included all randomized subjects and was used
to analyze all BMD endpoints. The mean percentage change from
baseline for each of the BMD skeletal sites at month 12 was analyzed
using an analysis of covariance (ANCOVA) model including treatment
and adjusting for study day of BMD assessment, treatment by BMD-
assessment-day interaction, baseline BMD value, DXA machine type,
and baseline BMD value by DXA-machine-type interaction. Summary
statistics for the results included least-squares means point estimates
of the mean percentage change from baseline for each treatment
group at month 12. The 95% two-sided conﬁdence intervals (CIs) and
associated p-values were provided for the treatment difference between
the least-squares means at month 12 for denosumab and risedronate
for each skeletal site.
The pre-speciﬁed primary analytical approach for BMD endpoints
employed an imputation for missing baseline and post-baseline BMD.
For each anatomical site, missing baseline BMD values were imputed
with the mean of all non-missing baseline BMD data from the same
corresponding machine type (Hologic or Lunar). Missing post-baseline
BMD values were imputed with the predicted values from the regression
model based on baseline covariates of each individual subject. Other
sensitivity analyses and an additional post-hoc analysis based on subjects
with complete data were also performed. Since none of these analyses
changed the overall conclusions of the ﬁndings, this manuscript will
focus on ﬁndings from the pre-speciﬁed primary analysis.
The primary ANCOVA analysis mentioned above was repeated
controlling for pre-speciﬁed covariates (baseline age, prior alendronate
treatment [duration, time since initiation, time since discontinuation,
and branded or generic alendronate], previous osteoporotic fractures,
and baseline sCTX-1), individually and simultaneously. Moreover, all
BMD endpoints were analyzed by each covariate subgroup, and the
treatment-by-subgroup interaction term was further assessed in the
ANCOVA model. If the p-value of an interaction term was ≥0.05, the
quantitative treatment-by-subgroup interaction was considered not
signiﬁcant. If the quantitative interaction was signiﬁcant, the Gail and
Simon test [12] was used to assess the qualitative interaction at the 5%
signiﬁcance level.
The least signiﬁcant change (LSC) in BMD measurements for the
total hip, femoral neck, and lumbar spine was calculated from the
duplicate DXA scans. The proportions of subjects with a BMD change
at month 12 b LSC and ≥LSC at each skeletal site were evaluated
between treatment groups. The LSC is an important determinant in
evaluating BMD changes because it reﬂects the smallest change in
BMD that, when equaled or exceeded, allows the physician to conclude
whether or not there has been a statistically signiﬁcant change in the
measurement.An additional post-hoc subgroup analysis was conducted in subjects
at higher risk vs the remaining at-risk subjects. Higher-risk subjectsmet
any 1 of the following:
1) Baseline BMD T-score≤−2.5 at the total hip or femoral neck,
2) Baseline BMD T-score≤−1.0 at the total hip or femoral neck and
prior osteoporotic fracture, or
3) Baseline sCTX-1 N 0.9 ng/mL (upper limit of premenopausal
reference range) and BMD T-scores ≤ −2.0 at the total hip or
femoral neck.
Treatment comparisons of median percentage change from baseline
in sCTX-1 at each time point were analyzed using aWilcoxon rank-sum
test.
The safety analysis set included all randomized subjects who
received ≥1 dose of investigational product. Incident fractures were
reported as AEs. Two adjudication committees evaluated potential
safety events of atypical femoral fractures and osteonecrosis of the
jaw (ONJ). All subtrochanteric, mid-shaft, and distal femur fractures
were evaluated to determine consistencywith the deﬁnition of atypical
femoral fracture [13]; AEs potentially associated with ONJ were
identiﬁed based on a pre-deﬁned list of terms in theMedical Dictionary
for Regulatory Activities (MedDRA) and adjudicated.Results
Subjects
Among 1431 screened subjects, a total of 870 (435 risedronate, 435
denosumab) subjects were enrolled and randomized into the study; 824
(94.7%) subjects (402 risedronate, 422 denosumab) completed the study,
and 46 (5.3%) subjects (33 risedronate, 13 denosumab) discontinued the
study (Fig. 1). The most frequent reasons for study discontinuation
were consent withdrawn (15 risedronate, 7 denosumab) and AEs
(13 risedronate, 3 denosumab). Although enrolled subjects were
considered suboptimally adherent to alendronate therapy at study
entry, as expected in the conduct of a clinical trial, compliance with
study medication was satisfactory, with 369 (85.8%) subjects in the
risedronate group who received ≥24 tablets through month 12, and
415 (96.7%) subjects in the denosumab group who received the 2
scheduled injections.
Baseline demographics and key characteristics among enrolled
subjects are shown in Table 1. The mean (SD) age was 67.7 (6.9)
years, most subjects were white or Caucasian (97.6%), and the mean
(SD) baseline total hip, femoral neck, and lumbar spine BMD T-scores
were −1.6 (0.9), −1.9 (0.7), and −2.2 (1.2), respectively. Based on
subject-reported fracture history, the number of subjects with a history
of any fracture was 431 (49.5%); with an osteoporotic fracture (all
fractures excluding skull, facial bones, ﬁngers, and toes and not
associated with known high-trauma severity or pathological fractures)
was 301 (34.6%); and with a vertebral fracture was 82 (9.4%). Sixty-
one (7.0%) subjects had a recent osteoporotic fracture b1 year prior to
the study.
Themedian (interquartile range [IQR]) durations of prior alendronate
use were 27.2 (8.9, 64.0) months for risedronate-treated subjects and
20.0 (5.7, 52.5) months for denosumab-treated subjects (Table 1). The
majority of subjects had used alendronate for ≥12 months (69.2%
of risedronate and 63.9% of denosumab subjects), and most had
discontinued therapy for b12months (86.7% of risedronate and 85.3%
of denosumab subjects; Table 1). There were 126 (29.0%) risedronate-
treated subjects and 133 (30.6%) denosumab-treated subjects who
were still receiving alendronate at study entry. Consistent with low
adherence to previous alendronate therapy, the median baseline
serum levels of sCTX-1 were 0.32 and 0.33 ng/mL in the risedronate-
and denosumab-treated groups, respectively.
Fig. 1. Subject disposition.
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Bone mineral density
Denosumab signiﬁcantly increased BMD at the total hip atmonth 12
with a mean percentage change from baseline of 2.0% (95% CI: 1.8%,
2.3%); the difference in mean percentage change from risedronate was
1.6% (95% CI: 1.2%, 2.0%; p b 0.0001). Denosumab also signiﬁcantly
increased BMD at the femoral neck and lumbar spine at month 12
with a mean percentage change from baseline of 1.4% (95% CI: 1.0%,
1.7%) and 3.4% (95% CI: 3.1%, 3.8%), respectively, and compared with
risedronate, a difference in mean percentage change between the
treatment groups of 1.4% (95% CI: 0.9%, 1.8%; p b 0.0001) and 2.3%
(95% CI: 1.8%, 2.8%; p b0.0001), respectively (Fig. 2).
Since DXAmeasurements were performed in duplicate, the LSC in the
BMDmeasurements was able to be calculated to further characterize the
BMDchanges atmonth 12withdenosumabor risedronate treatment. The
calculated LSCswere 1.89% at the total hip, 3.14% at the femoral neck, andTable 1
Baseline demographics and clinical characteristics.
Risedronate
(N=435)
Denosumab
(N=435)
Age, years 67.7 (6.8) 67.8 (7.0)
Years since menopause 20.1 (8.8) 20.2 (8.9)
History of osteoporotic fracture, n (%)a 150 (34.5) 151 (34.7)
Total hip BMD T-score −1.6 (0.8) −1.6 (0.9)
Femoral neck BMD T-score −1.9 (0.7) −1.9 (0.8)
Lumbar spine BMD T-score −2.3 (1.1) −2.2 (1.2)
Serum 25-hydroxyvitamin D, ng/mL 34.9 (13.5) 34.4 (13.2)
Duration of prior alendronate use, months
Median (IQR) 27.2 (8.9, 64.0) 20.0 (5.7, 52.5)
0 to b12months, n (%) 133 (30.6) 157 (36.1)
≥12months, n (%) 301 (69.2) 278 (63.9)
Time since prior alendronate use, n (%)
0 to b12months 377 (86.7) 371 (85.3)
≥12months 45 (10.3) 46 (10.6)
Never took alendronate 12 (2.8) 18 (4.1)
Still taking alendronate at study entry, n (%) 126 (29.0) 133 (30.6)
Serum CTX-1, ng/mL, median (IQR)
Lower tertile: b0.23 0.16 (0.12, 0.19) 0.16 (0.12, 0.19)
Middle tertile: ≥0.23 to b0.37 0.29 (0.26, 0.33) 0.29 (0.25, 0.33)
Upper tertile: ≥0.37 0.53 (0.45. 0.63) 0.52 (0.44, 0.68)
Values are means (standard deviations) unless otherwise indicated. N = number of
subjects randomized. IQR= interquartile range.
a Any fracture not including skull, facial bones,ﬁngers, and toes, and not associatedwith
known high-trauma severity or pathological fractures.2.16% at the lumbar spine. Atmonth 12, a signiﬁcantly greater percentage
of denosumab-treated subjects as compared with risedronate-treated
subjects had BMD gains that were ≥LSC at the total hip (49% vs 20%,
p b 0.0001), femoral neck (24% vs 14%, p b 0.0001), and lumbar spine
(64% vs 32%, pb0.0001; Fig. 3).
After controlling for additional covariates (baseline age, prior
alendronate treatment [duration, time since initiation, time since
discontinuation, and branded or generic alendronate], previous
osteoporotic fractures, and baseline sCTX-1), individually and
simultaneously in the primary ANCOVAmodel, the effect of denosumab
treatment remained consistent and signiﬁcant (p b 0.0001 in each
covariate analysis) at all 3 skeletal sites.
When primary and secondary endpoints were analyzed by
subgroups—including by age, prior alendronate treatment (duration,
time since initiation, time since discontinuation, and branded or generic
alendronate), previous osteoporotic fractures, at-risk/higher-risk subjects,
and baseline sCTX-1 tertile—the results demonstrated that increases in
total hip, femoral neck, and lumbar spine BMD were numerically greater
in the denosumab group than in the risedronate group at month 12 in all
subgroups.sCTX-1
There was a signiﬁcant decrease in sCTX-1 from baseline in both
treatment groups at month 1 and a signiﬁcantly greater reduction wasFig. 2. Percentage change in BMD frombaseline atmonth 12. Data are least-squaresmeans
and 95% conﬁdence intervals. *p b 0.0001 denosumab vs risedronate.
Fig. 3. Percentage of subjects with ≥least signiﬁcant change (LSC) in BMD at month 12.
*p b 0.0001 denosumab vs risedronate.
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treatment: median (IQR) percentage change of −77.7% (−85.9%,
−67.6%) for denosumab and−17.0% (−36.8%,−1.6%) for risedronate
(p b 0.0001; Fig. 4). Median reductions in sCTX-1 at month 6 were also
greater in the denosumab group compared with the risedronate group:
median (IQR) percentage change of −60.6% (−77.0%, −48.8%) for
denosumab and –22.5% (−41.9%, 11.4%) for risedronate (pb0.0001).
BMD/sCTX-1 associations and determinants of response
The BMD mean percentage changes from baseline at month 12 by
tertiles (b0.23, ≥0.23 to b0.37, and ≥0.37 ng/mL) of baseline sCTX-1
for each skeletal site are reported in Fig. 5. This additional analysis showed
that subjects treated with denosumab, compared with risedronate,
demonstrated signiﬁcantly greater gains in lumbar spine BMD at month
12 at each tertile of baseline sCTX-1 (pb0.01; Fig. 5). Signiﬁcantly greater
gains in total hip and femoral neck BMD were also observed among
subjects in the middle and highest tertiles of baseline sCTX-1 (p b 0.01).
At all sites the magnitude of the BMD gain was signiﬁcantly more
pronounced in the middle and highest sCTX-1 tertiles (treatment-by-
sCTX-1 tertile interaction p-valuesb0.01).
The post-hoc analysis showed that nearly half of the enrolled
population was at higher risk for fracture: 46.4% and 45.5% of
risedronate- and denosumab-treated subjects, respectively. These
higher-risk subjects demonstrated BMD gains that were consistent
with ﬁndings in the overall population (Fig. 6).Fig. 4. Percentage change in sCTX-1 from baseline. Data are medians and interquartile
range (IQR). n = number of subjects with values at baseline and at the time point of
interest. *p b 0.0001 denosumab vs risedronate.Safety
Overall, the subject incidences of AEs were 293 subjects (68.3%) in
the risedronate group and 269 subjects (62.7%) in the denosumab
group, with the most frequently experienced AEs (≥4% in either
treatment group [risedronate, denosumab]) being hypertension
(2.6%, 4.2%), arthralgia (4.4%, 4.0%), nasopharyngitis (4.2%, 3.5%), and
constipation (5.1%, 3.3%). Most of the AEs in both groups were
categorized as being either mild or moderate in severity (Table 2).
SAEs were reported for 8.2% of risedronate-treated subjects and 7.7%
of denosumab-treated subjects. There was no evidence of clustering of
SAEs within any given system organ class or high-level group term
in either treatment group. SAEs reported for ≥2 denosumab-treated
subjects were osteoarthritis, radius fracture, cerebral ischemia,
cerebrovascular accident, arthralgia, and atrial ﬁbrillation; these SAEs
were each experienced by 2 (0.5%) denosumab-treated subjects. In
the risedronate treatment group, the most frequently reported SAEs
(2 [0.5%] subjects each) were breast cancer and coronary artery
stenosis; all other SAEs were experienced at an incidence of 1 subject
each. One death due to cardiac arrest was reported in a risedronate-
treated subject. No deaths were reported in the denosumab group.
This study was not designed with adequate statistical power to
compare the incidence of fractures between treatment groups;
descriptive results are reported here. Fractures reported as AEs
regardless of trauma severity occurred in 4.0% (17) of subjects in
the risedronate treatment group and in 5.4% (23) of subjects in
the denosumab treatment group. The incidence of clinical fractures
was similar between treatment groups (15 subjects [3.5%] in the
risedronate group, 19 subjects [4.4%] in the denosumab group), with
the anatomical distribution of fractures generally being typical for
postmenopausal women with low bone mass. Of the subjects who
had a clinical fracture on study, 10 (66.7%) subjects in the risedronate
group and 6 (31.6%) subjects in the denosumab group had a medical
history of osteoporotic fracture.
The independent adjudication committee for atypical femoral fracture
evaluated the 2 diaphyseal femoral fractures; one occurred after a trauma
described as severe by the investigator while the other was characterized
by cortical thickening without a cortical break. Both fractures were
adjudicated as not consistent with the ASBMR deﬁnition of atypical
femoral fracture [13]. There were no adjudicated cases of ONJ. No case
of fracture healing complication was reported. No subject tested positive
for anti-denosumab binding antibodies at month 12. No subject was
reported to have hypocalcemia or other clinically signiﬁcant laboratory
ﬁndings.
Discussion
This open-label, phase 3 study shows that in postmenopausal women
who were previously suboptimally adherent to alendronate therapy,
transitioning to denosumab was more effective than transitioning to
risedronate as measured by BMD and sCTX-1. While BMD and
bone turnover are not the sole predictors of fracture risk, they are
important considerations in the overall management and monitoring
of osteoporosis treatment. In the denosumab group, we observed a
signiﬁcant increase in BMD, higher than in the risedronate group, at
all measured skeletal sites. In addition, duplicate DXA measurements
at baseline and at the end of the study permitted assessment of LSC,
andmore subjects treated with denosumab compared with risedronate
showed gains ≥LSC at each anatomical site measured. Of note, this
study was not powered to assess the relationship between these
changes in BMD with denosumab vs risedronate and the anti-fracture
effect. Denosumab also signiﬁcantly reduced sCTX-1 during the 6-
month dosing interval compared with risedronate. With denosumab,
maximal reduction of sCTX-1 was rapidly achieved following
administration, with levels of sCTX-1 indicating release of inhibition at
the end of the dosing interval, an observation that has been seen in
Fig. 5. Percentage change in BMD from baseline at month 12 by baseline sCTX-1. Data are least-squares means and 95% conﬁdence intervals. n=number of subjects with data. *pb 0.01
denosumab vs risedronate. Treatment-by-subgroup interaction p-value is N0.05.
53C. Roux et al. / Bone 58 (2014) 48–54other clinical trials with denosumab [14–16]. This observation contrasts
with sCTX-1 reduction for the risedronate group, which remained
relatively stable after reaching a nadir by month 1.
These results conﬁrm the data obtained in another switching study
[10] conducted in osteoporotic subjects (T-score=−2.6 at the lumbar
spine vs T-score=−2.2 in the current study). In contrast, in subjects
transitioning from alendronate to a single infusion of zoledronic acid,
BMD values remained unchanged at 12months in thosewho transitioned
to zoledronic acid at 12months [17]. While the difference in BMD
outcomes may be related to suboptimal adherence to previous
alendronate treatment in our study, sCTX-1 at study entry was
reduced in both treatment groups (b0.3 ng/mL).
Bisphosphonates are currently themost commonly utilized treatment
for osteoporosis, and alendronate is generally prescribed as a ﬁrst-line
therapy. Transitioning therapies may occur due to difﬁcult dosing
regimens, side effects, or perceived treatment failure, but the incidence
is not known. The practice of cycling patients from oral alendronate
through multiple, other oral bisphosphonates occurs despite a lack of
evidence demonstrating additional beneﬁts in BMD, bone turnover
markers, or overall adherence and effectiveness. Thus, studies such as
this one can be used not only to assess the pharmacological effects of
the drugs, but also to help physicians choose the best therapeutic
strategy. Of particular interest is the observation that subjects with
the highest level of remodeling at baseline achieved the greatest gainsFig. 6. Percentage change in BMD from baseline at month 12 in higher-risk subjects. Data are l
Treatment-by-subgroup interaction p-value is N0.05. A higher-risk subject is deﬁned as subje
T-score≤−1.0 at total hip or femoral neck and prior fracture, or sCTX-1 N 0.9 ng/mL andin BMD, something that was not observed in subjects whowere treated
with risedronate. Greater reductions in sCTX-1 and greater gains in BMD
associated with denosumab treatment have similarly been observed
when compared with alendronate in subjects who were treatment-
naïve [9] or pre-treated with alendronate [10], and when compared
with ibandronate in subjects pre-treated with an oral bisphosphonate
[18].
Low BMD is an important and modiﬁable risk factor for fracture in
postmenopausal women, and with denosumab, which has a unique
mechanism of action, a strong relationship between BMD increases
and anti-fracture efﬁcacy has been shown [19]. The gains in BMD
observed in the current study are statistically signiﬁcant as reﬂected in
the proportion of individuals who had BMD gains ≥LSC.
In this study, therewas no BMD-based inclusion criterion, and it was
the investigator's responsibility to assess the appropriateness of the
potential study subject to receive prolonged osteoporosis therapy. To
better deﬁne characteristics of the study population, we developed a
higher-risk subgroup by BMD threshold, BMD threshold plus fracture,
or baseline sCTX-1 upper limit to identify within the study population
a group thatwould be expected to receive highest priority for prolonged
therapy.We found that one-third of this subgrouphadprior osteoporosis-
related fractures. Interestingly, this subgroup showedBMDresponses that
were consistentwith the overall study cohort, demonstrating consistency
of effect of denosumab independently of prevalent fractures.east-squares means and 95% conﬁdence intervals. *p b 0.0001 denosumab vs risedronate.
ct with baseline BMD T-score ≤ −2.5 at total hip or femoral neck, or baseline BMD
BMD T-scores≤−2.0 at total hip or femoral neck.
Table 2
Summary of subject incidence of adverse events.
Event, n (%) Risedronate
(N=429)
Denosumab
(N=429)
Adverse events regardless of relationship to treatment
All 293 (68.3) 269 (62.7)
Serious 35 (8.2) 33 (7.7)
Fatal 1 (0.2) 0
Leading to IP discontinuation 19 (4.4) 10 (2.3)
Selected serious adverse events
Infections 5 (1.2) 5 (1.2)
Pancreatitis 1 (0.2) 1 (0.2)
Cellulitis 1 (0.2) 0
Selected adverse events of interest
Eczema 5 (1.2) 4 (0.9)
Fracture 17 (4.0) 23 (5.4)
Hypersensitivity 15 (3.5) 8 (1.9)
Malignancy 8 (1.9) 6 (1.4)
N=all subjects who received ≥1 dose of IP; n=number of subjects reporting≥1 event.
IP= investigational product.
54 C. Roux et al. / Bone 58 (2014) 48–54No new safety risks were identiﬁed in this open-label study, and the
safety proﬁle of denosumabwas consistentwith that previously observed
for denosumab in clinical trials with the same 60mg Q6M dosage. Bone
safety is a key issue of prolonged treatment, in particular in the context
of prior alendronate therapy, because of the long-term bone retention of
this drug. The subject incidences of AEs and SAEs were similar between
the treatment groups. This study was not designed with adequate
statistical power to evaluate anti-fracture efﬁcacy of denosumab and
risedronate. Similar numbers of clinical fractures were reported by
investigators for risedronate- and denosumab-treated subjects, and
location of incident fractures was not unusual. Many of these subjects
who sustained a fracture on-study had a history of prevalent fractures
at study entry, increasing their risk for future fracture.
Conclusion
In conclusion, in postmenopausalwomenwhowere previously taking
alendronatewith suboptimal adherence, transitioning to denosumabwas
well tolerated and more effective to increase BMD and lower bone
turnover than switching to risedronate.
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